Skip to main content

Table 2 Scores for Primary and Secondary Outcomes Over Time (N = 220)

From: Exploring the efficacy of an electronic symptom assessment and self-care intervention to preserve physical function in individuals receiving neurotoxic chemotherapy

 

Mean (SD)

Mean Change from Baseline (SD)

Model Estimate (95% CI, p)b

Outcomesa

Intervention

Control

Intervention

Control

Interaction effect

Physical Function

 Baseline

87.4 (15.6)

90.2 (12.7)

  

2.75 (0.65, 4.86),

p = 0.011

 Time 2

85.2 (17.5)

83.9 (16.7)

−2.2 (15.2)

−6.3 (14.1)

 Time 3/4

84.5 (16.1)

81.8 (17.0)

−2.9 (15.0)

−8.5 (16.8)

Depression

 Baseline

4.2 (4.4)

3.5 (3.4)

  

−0.72 (−1.23, − 0.22)

p = 0.005

 Time 2

4.9 (4.0)

5.4 (3.3)

0.7 (3.5)

1.9 (3.2)

 Time 3/4

3.9 (3.6)

4.64 (4.3)

−0.3 (3.4)

1.2 (4.2)

Fatigue

 Baseline

27.7 (20.5)

23.8 (18.9)

  

− 3.12 (−6.29, 0.04)

p = 0.053

 Time 2

37.6 (23.5)

41.0 (22.8)

9.8 (21.0)

17.3 (22.7)

 Time 3/4

34.4 (21.8)

36.7 (21.0)

6.7 (21.4)

12.9 (23.8)

CIPN Sensory

 Baseline

3.9 (9.6)

3.3 (6.6)

  

−1.67 (−3.90, 0.55)

p = 0.141

 Time 2

7.8 (11.9)

6.4 (10.3)

4.0 (9.7)

3.1 (9.1)

 Time 3/4

12.9 (14.3)

15.7 (18.2)

9.0 (14.2)

12.4 (19.0)

CIPN Motor

 Baseline

4.5 (10.1)

2.5 (4.0)

  

−1.3 (−2.95, 0.35)

p = 0.122

 Time 2

5.7 (11.5)

5.3 (7.4)

1.2 (6.2)

2.8 (6.6)

 Time 3/4

8.9 (12.7)

9.6 (13.4)

4.5 (11.7)

7.1 (13.1)

Current Pain Intensity

 Baseline

1.7 (1.9)

1.5 (1.9)

  

−0.09 (−0.37, 0.18)

p = 0.500

 Time 2

1.72 (1.9)

1.6 (1.9)

0.03 (2.3)

0.10 (2.2)

 Time 3/4

1.7 (1.9)

1.7 (1.8)

0.00 (1.8)

0.19 (2.2)

Insomnia

 Baseline

28.4 (24.9)

27.7 (26.8)

  

−0.62 (−4.58, 3.35)

p = 0.760

 Time 2

31.2 (29.6)

33.6 (25.9)

2.8 (31.6)

6 (28.7)

 Time 3/4

28.3 (24.9)

28.9 (27.0)

−0.05 (24.6)

1.19 (32.2)

High Cumulative Dose Category (n = 84)

 CIPN Sensory

     

  Baseline

4.0 (12.3)

3.5 (6.2)

  

−5.70 (−9.89, −1.60)

p = 0.007

  Time 2

8.1(12.7)

7.7 (13.0)

4.1 (10.8)

4.2 (12.7)

  Time 3/4

13.8 (14.3)

24.7 (22.4)

9.8 (14.0)

21.2 (23.9)

CIPN Motor

  Baseline

4.2 (10.7)

2.0 (3.4)

  

−3.45 (−6.70, −0.19)

p = 0.039

  Time 2

4.9 (10.3)

5.1 (7.3)

0.7 (6.0)

3.2 (6.9)

  Time 3/4

8.6 (10.7)

13.3 (17.8)

4.4 (12.9)

11.3 (17.6)

  1. This table describes differences in mean scores for the primary and secondary outcomes over time between treatment groups. There were no statistically significant differences in baseline scores between groups for any outcome (p > 0.05)
  2. aOutcomes include the mean and standard deviation at each time point, the mean change from baseline and standard deviation of this change at the two follow-up time points, and the results from fitting a mixed model
  3. bThis effect represents interaction of time and treatment. For example, if the scores are decreasing over time and the interaction coefficient is negative (positive), this means the intervention group scores decrease at a higher (lower) rate than the control group scores. Alternatively, if the scores are increasing over time and the interaction coefficient is negative (positive), this means the intervention group scores increase at a lower (higher) rate than the control group scores. In this data, scores for all outcomes except for the physical assessment are increasing over time (main effects) and interaction coefficients are negative. Therefore, the interpretation for all outcomes except for physical function is that the intervention group scores increase at a lower rate than the control group scores. For physical function, the intervention group scores decrease at a lower rate as compared to the control group scores
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us